Goldman Sachs sees big gains ahead for Merus on the back of the company's cancer treatment.
The firm initiated coverage of the cancer therapeutics stock with a buy rating on Wednesday, alongside a $73 per share price target.
Law said the antibody has already shown promising results and can be a key growth driver for the stock moving forward.
MRUS YTD mountain Merus stock.
Merus stock has advanced more than 56% already in 2024.
Persons:
Goldman Sachs, Richard Law, Law, peto
Organizations:
Merus